BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol 2021;39:2803-15. [PMID: 34077237 DOI: 10.1200/JCO.20.03611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cowzer D, Janjigian YY. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer 2022. [PMID: 35179774 DOI: 10.1002/cncr.34140] [Reference Citation Analysis]
2 Bridges S, Thomas B, Radhakrishna G, Hawkins M, Holborow A, Hurt C, Mukherjee S, Nixon L, Crosby T, Gwynne S. SCOPE 2 – Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.03.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wilson BF, Dang J, Masuda D, Cowler T. Esophageal Adenocarcinoma in an Active Duty Sailor: A Case Report. Mil Med 2022:usac096. [PMID: 35355077 DOI: 10.1093/milmed/usac096] [Reference Citation Analysis]
4 Zhao Z, Yang S, Zhou A, Li X, Fang R, Zhang S, Zhao G, Li P. Small Extracellular Vesicles in the Development, Diagnosis, and Possible Therapeutic Application of Esophageal Squamous Cell Carcinoma. Front Oncol 2021;11:732702. [PMID: 34527593 DOI: 10.3389/fonc.2021.732702] [Reference Citation Analysis]
5 Buckstein MH, Anker CJ, Chuong MD, Hawkins MA, Kharofa J, Olsen JR. CROSSing into New Therapies for Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics 2022;113:5-10. [DOI: 10.1016/j.ijrobp.2021.12.177] [Reference Citation Analysis]
6 Hall WA, Paulson E, Li XA, Erickson B, Schultz C, Tree A, Awan M, Low DA, McDonald BA, Salzillo T, Glide-Hurst CK, Kishan AU, Fuller CD. Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians. CA Cancer J Clin 2021. [PMID: 34792808 DOI: 10.3322/caac.21707] [Reference Citation Analysis]
7 Obermannova R, Selingerova I, Rehak Z, Jedlicka V, Slavik M, Fabian P, Novotny I, Zemanova M, Studentova H, Grell P, Zdrazilova Dubska L, Demlova R, Harustiak T, Hejnova R, Kiss I, Vyzula R. PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study. Ther Adv Med Oncol 2021;13:17588359211065153. [PMID: 35035533 DOI: 10.1177/17588359211065153] [Reference Citation Analysis]
8 Pointer DT Jr, McDonald JA, Naffouje SA, Mehta R, Fleming JB, Fontaine JP, Lauwers GY, Frakes JM, Hoffe SE, Pimiento JM. The effect of histologic grade on neoadjuvant treatment outcomes in esophageal cancer. J Surg Oncol 2022. [PMID: 35578777 DOI: 10.1002/jso.26921] [Reference Citation Analysis]